News | April 30, 2026
RPG Life Sciences reports Rs 707.5 crore revenue in FY26, 8% annual growth
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The medtech firm strengthens its full-stack remote cardiac monitoring platform, achieves 11x revenue growth, and advances its global expansion plans
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
Union health minister urges graduates in Chandigarh to combine technological excellence with compassion in medical practice
Landmark agreement opens market access, mobility pathways, and institutional collaboration for Ayurveda, Yoga, and holistic healthcare services
Acquisition enhances integrated pharmacovigilance platform, combining AI, automation, and services to improve compliance, efficiency, and end-to-end clinical safety operations
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
Subscribe To Our Newsletter & Stay Updated
